

## Electronic Acknowledgement Receipt

<b>EFS ID:</b>	7314518
<b>Application Number:</b>	10529670
<b>International Application Number:</b>	
<b>Confirmation Number:</b>	8433
<b>Title of Invention:</b>	Substituted (thiazol-2-yl)-amide or sulfonamide as glycol kinase activators useful in the treatment of type 2 diabetes
<b>First Named Inventor/Applicant Name:</b>	Gregory Raymond Bebernitz
<b>Customer Number:</b>	75074
<b>Filer:</b>	Theresa Ann Devlin/Marcus Hall
<b>Filer Authorized By:</b>	Theresa Ann Devlin
<b>Attorney Docket Number:</b>	PAT032711-US-PCT
<b>Receipt Date:</b>	30-MAR-2010
<b>Filing Date:</b>	15-AUG-2005
<b>Time Stamp:</b>	13:14:37
<b>Application Type:</b>	U.S. National Stage under 35 USC 371

### Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$820
RAM confirmation Number	10605
Deposit Account	504409
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. 1.492 (National application filing, search, and examination fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.19 (Document supply fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.20 (Post Issuance fees)

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

## File Listing:

Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1	Amendment After Final	32711-AmendmentAF.pdf	1602399	no	8
			6a11cb22d5363d8a84c3464bca520d0f3546ed7c		
Warnings:					
Information:					
2	Notice of Appeal Filed	PAT032711-NoticeofAppeal.pdf	306746	no	1
			3830dbb7531e7c53cbb4e9a6b9ba567aab11f8e4		
Warnings:					
Information:					
3	Terminal Disclaimer Filed	32711-TerminalDisclaimer11547046.pdf	371264	no	1
			b48c58c023eaa3d2e1ba8ca4b0dfe7ff80455ac		
Warnings:					
Information:					
4	Terminal Disclaimer Filed	32711-TerminalDisclaimer12088608.pdf	376838	no	1
			9844c7c2fd5568818e7738d7594f20df58b3386		
Warnings:					
Information:					
5	Fee Worksheet (PTO-875)	fee-info.pdf	32416	no	2
			2d7d253ccc4a49ed4884c69ce042375c072d0635		
Warnings:					
Information:					
Total Files Size (in bytes):			2689663		

**This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.**

**New Applications Under 35 U.S.C. 111**

**If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.**

**National Stage of an International Application under 35 U.S.C. 371**

**If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.**

**New International Application Filed with the USPTO as a Receiving Office**

**If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.**